$MMM (+0,05%)

Morgan Stanley upgraded 3M (NYSE:MMM) from a previous investment rating of "underweight" to "equal weight" late Tuesday, saying the industrial conglomerate appears to be turning a corner after several years of sluggish performance.

Morgan Stanley now values the stock at 21 times 2026-27 earnings, a discount of around 10% to the S&P 500 and reflecting what the company sees as a more balanced risk/reward profile.

The company cited 3M's self-help initiatives - including product innovation, operational improvements and a focus on consumables - as drivers of more sustainable growth.

Morgan Stanley raised its price target for 3M (NYSE:MMM) to $160 per share from $130.

Although risks related to tariffs, litigation liabilities and potential channel destocking remain, Morgan Stanley said the outlook for 3M improved as the growth trend becomes more aligned with U.S. industrial production. "We now view 3M (MMM) as relatively well positioned from an audit perspective, which should obviate the need for underperformance," the report states.

$NDAQ (+0,34%)
$RTX (+0,57%)
$KO (+0,07%)
$MMM (+0,05%)
$NOC (+0,21%)
$LMTB34
$OR (+0,45%)
$TXN (+0,5%)
$NFLX (-0,1%)
$HEIA (+0,41%)
$SAAB B (+3,2%)
$UCG (+0,44%)
$BARC (+0,9%)
$GEV (+0,29%)
$TMO (+1,2%)
$T (+0,18%)
$MCO (+0,07%)
$IBM (+0,19%)
$SAP (+0,51%)
$TSLA (+0,14%)
$AAL (+0,75%)
$FCX (+0,38%)
$HON (+0,16%)
$DOW (+0,48%)
$NOKIA (-0,31%)
$TMUS (+0,57%)
$INTC (+0,13%)
$NEM (-4,73%)
$F (-3,6%)
$PG (+0,03%)
$GD (+1,13%)

I closed two historical positions:

• $BTI (+0%) with a gain of +66%
• $MMM (+0,05%) with a gain of +50%

With the freed capital I opened new positions on Target ($TGT (-0,02%) ) and Merck ($MRK (+0,27%) ), to continue diversifying and target sectors that I see as solid in the medium to long term.

📈 Always with the idea of growing the portfolio in a balanced and sustainable way.

After 3M halved the dividend and the position became too large in percentage terms, I decided to sell and shift into the $TDIV (+0,28%) and shift into the

The industrial group $MMM (+0,05%) exceeded market expectations in the second quarter of 2025 - at least in terms of turnover and profit:

• Turnover: USD 6.34 billion
• → Expectation: USD 6.10 billion
• → +1,4 % compared to the previous year, 4% above estimates
• Adjusted earnings per share (EPS): USD 2.16
• → Expectation: USD 2.01
• → 7.4 % above expectations

📈 Management has raised the annual forecast for adjusted earnings to USD 7.88 per share (mean value) - a slight increase of 1,6 %.

But there are also downsides:

• Operating margin: 18 % (previous year: 20.3 %)
• Free cash flow:
  USD -1.16 billion (previous year: USD +1.17 billion)
• Organic sales growth: +1.5% YoY (constant year-on-year)

📌 Market capitalization: USD 85.59 bn

💬 Conclusion: 3M delivers solid sales and earnings figures, but the negative free cash flow and falling margin raise questions. The share remains exciting - especially for long-term investors.

My YouTube channel for stock analysis: www.youtube.com/@Verstehdieaktie

As the earnings season starts again, here is a summary of the most important figures next week.

$JPM (+0,39%)
$C (+0,39%)
$WFC (+0%)
$BLK (-0,25%)
$JNJ (+0,62%)
$GS (+0,27%)
$BAC (+0,3%)
$AA (-2,06%)
$ASML (+0,95%)
$PLD (-0,04%)
$UAL (-0,18%)
$KMI (+0,83%)
$PEP (+0,26%)
$ABT (+0,16%)
$Netflix
$TSM (+1,2%)
$USB (+0,26%)
$IBKR (+0,79%)
$AXP (+0,34%)
$MMM (+0,05%)

Hi folks ,

I would like to add more stocks to my portfolio and would appreciate your opinion and vote. Which company/sector do you think is missing? And no, I'm not looking for ETF advice😂.

Also, I've been on the stock market since 2021 and have invested around €80,000 in the last 12 months.

The following stocks are available:

$MMM (+0,05%) - $3350 (+6,67%) - $1211 (-0,54%) - $UNH (+0,49%) - $KER (-0,48%) - $PEP (+0,26%) - $DJT (+0,88%)

I look forward to your opinion!

$JNJ (+0,62%)

The ongoing lawsuits over allegedly carcinogenic talcum powder products have put Johnson under pressure.

A US federal judge has refused to resolve the matter via insolvency proceedings.

The financial risk at Johnson is high, new uncertainty in the strategic direction.

Johnson the new Bayer $BAYN (+0,13%) and 3M $MMM (+0,05%) ?

Bottomless pit, the share has been in a volatile downward trend since 2022. Once again, the upper boundary line was not broken.